Work

Abstract CT038: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct038

Authors: Francis Worden, Cristina Rodriguez, Amita Patnaik, Justin Call, A. Dimitrios Colevas, Ammar Sukari, Trisha Wise-Draper, Nabil Saba, Koho Iizuka, Hong Tang, Varun N. Kapoor, Douglas Adkins

Institutions: University of Michigan, Fred Hutch Cancer Center, South Texas Accelerated Research Therapeutics, Stanford Cancer Institute, Stanford University, The Barbara Ann Karmanos Cancer Institute, University of Cincinnati, Emory University, Coherus BioSciences (United States), Washington University in St. Louis

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822265

Cites:

Cited by: 2

Related to: 10